10 g/dL (3% vs 15%), dose modification of PEGASYS (30% vs
36%) and COPEGUS (19% vs
38%) and of withdrawal from treatment (5% vs
15%) compared to patients treated for 48 weeks with PEGASYS and 1000 mg or 1200 mg COPEGUS. On the other hand the overall incidence of adverse events appeared to be similar in the two treatment groups.
The most common serious adverse event (3%) was bacterial infection (eg, sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia).